January 11, 2007. A growth-factor drug commonly used to help cancer patients maintain levels of infection-fighting white blood cells during and after chemotherapy may stimulate growth of tumors in bones, a new study says.

The growth factor, called granulocyte colony-stimulating factor (G-CSF) is known by the trade names Neupogen, Neulasta and Granocyte.

G-CSF’s detrimental effect on bone tumors may be cancelled out by adding a bisphosphonate to the treatment.

These findings come from a study by researchers in St. Louis and bear out research years ago that showed that G-CSF weakens bone.

FULL STORY….

ZK-Epothilone (ZK-Epo) is a novel chemotherapy drug currently in clinical trials to see if it has an effect against advanced prostate, ovarian and breast cancer. ZK-Epo may work differently than Taxotere and other taxane drugs. It is being tested against all three cancers at centers across the USA and also in Argentina (for ovarian cancer) and Canada (for breast cancer) .
(full story…)

ZK-Epothilone (ZK-Epo) is a novel chemotherapy drug currently in clinical trials to see if it has an effect against advanced prostate, ovarian and breast cancer. ZK-Epo may work differently than Taxotere and other taxane drugs. It is being tested against all three cancers at centers across the USA and also in Argentina (for ovarian cancer) and Canada (for breast cancer) .

One of the medical centers now recruiting prostate cancer patients for this trial is Oregon Health and Science University (OSHU). The chief clinical investigator for the OSHU trial is Tomasz Beer, MD.
(full story…)